MedPath

Insulin Resistance in Atopic Dermatitis Patients

Completed
Conditions
Atopic Dermatitis
Registration Number
NCT05904509
Lead Sponsor
Bezmialem Vakif University
Brief Summary

The aim of the study is to determine the relationship between insulin resistance and disease duration and severity of atopic dermatitis.

Detailed Description

The aim of the study is to determine the relationship between insulin resistance and disease duration and severity of atopic dermatitis. EASI and SCORAD values and disease duration of atopic dermatitis patients are calculated during the examination. HOMA-IR blood test result is compared with the results.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
32
Inclusion Criteria
  • Atopic dermatitis patients confirmed by a dermatologist
Exclusion Criteria
  • patients younger than 2 years
  • patients older than 80 years
  • Atopic dermatitis patients without HOMA-IR result

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
SCORAD index12 months

Severity scoring of atopic dermatitis is calculated for each patient in the study. 6 intensity items (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, dryness); 2 subjective symptoms(itch, sleeplessness); body surface area are studied. Max score is 103.

HOMA-IR12 months

Patients' blood test show the result of fasting insulin (microU/L) x fasting glucose (mmol/L)/22.5

Duration of the disease12 months

The time from the first onset of symptoms of the disease to the present. The relationship between insulin resistance and disease duration is examined

EASI index12 months

Eczema Area and Severity Index is calculated for each patient in the study. Body surface area, 4 intensity items(erythema, induration, excoriation, lichenification) are studied. Max score is 72.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Bezmialem Vakif University Hospital

🇹🇷

Istanbul, Turkey

© Copyright 2025. All Rights Reserved by MedPath